---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-043933"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:06:28.551398+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Imunon Q3 net loss $4.9M; progressing toward Phase 3 for IMNN-001 in ovarian cancer

## Summary
- Net loss of $4.9M ($0.34 per share) vs $3.5M in Q3 2023; R&D expense $3.3M, G&A $1.7M.
- Cash, investments of $10.3M; expects to fund operations into Q3 2025.
- OVATION 2 topline: 11.1-month OS improvement, hazard ratio 0.74 in ITT; 15.7-month OS in per-protocol.
- Plan 500-patient Phase 3 study start Q1 2025; End-of-Phase 2 FDA meeting later in November 2024.
- Raised $10M gross proceeds in July 2024 registered direct offering; added General Counsel and SVP of Operations.

## SEC filing metadata
- accession: 0001493152-24-043933
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315224043933/0001493152-24-043933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315224043933/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-043933
- JSON: https://secwatch.observer/filing/0001493152-24-043933.json
- Plain text: https://secwatch.observer/filing/0001493152-24-043933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.